There are currently 443 clinical trials in Memphis, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including St. Jude Children's Research Hospital, Saint Jude Children's Research Hospital, Baptist Memorial Hospital and Cancer Center-Memphis and University of Tennessee Health Science Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944
Recruiting
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.
Gender:
ALL
Ages:
Between 12 months and 30 years
Trial Updated:
02/11/2025
Locations: Saint Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
Register for Updates
Barriers and Facilitators of Parent-Child Communication in Children With Cancer Predisposition
NCT05849155
Recruiting
Testing children, adolescents, and young adults (CAYA) for a genetic risk for cancer can help with early prevention and detection of cancers through regular follow-ups and medical care. After receiving genetic test results, CAYA may not accurately understand what their results mean, and parents are often unsure about talking with their CAYA about their genetic risk for cancer. By understanding how parents communicate with their CAYA, the investigators can improve future genetic education to redu... Read More
Gender:
ALL
Ages:
Between 10 years and 24 years
Trial Updated:
02/11/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Genetic Predisposition
Register for Updates
STOP AF First Post-Approval Study
NCT05227053
Recruiting
The STOP AF First PAS is a prospective, global, multi-center, observational trial.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Tennessee Methodist Physicians, Memphis, Tennessee
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
NCT06247787
Recruiting
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
02/11/2025
Locations: Saint Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Recurrent Juvenile Myelomonocytic Leukemia, Refractory Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome
Register for Updates
Follow-up Visit of High Risk Infants
NCT00009633
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: University of Tennessee, Memphis, Tennessee
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
DIAMOND AF Post-Approval Study
NCT05230524
Recruiting
The DIAMOND AF Post Approval study is a prospective, global, multi-center, non-randomized, single-arm observational trial
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Tennessee Methodist Physicians, Memphis, Tennessee
Conditions: Paroxysmal Atrial Fibrillation
Register for Updates
Generic Database of Very Low Birth Weight Infants
NCT00063063
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Tennessee, Memphis, Tennessee
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Register for Updates
Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-043)
NCT06428383
Recruiting
The primary objective of this study is to monitor the safety and tolerability of vericiguat.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
02/11/2025
Locations: Le Bonheur Children's Hospital ( Site 0007), Memphis, Tennessee
Conditions: Systolic Dysfunction
Register for Updates
Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis
NCT05930418
Recruiting
The overall purpose of this protocol is to identify subacute sepsis-associated cardiac disease in pediatric patients with cancer by CMR and evaluate the CMR findings during their follow-up. This will help inform heart failure management decision making. Evidence of dysfunction or elevated T2 values may inform adjustment of afterload reduction and beta blocker administration, and elevated ECV findings will suggest the need for increased surveillance for diastolic dysfunction. Primary Objectives:... Read More
Gender:
ALL
Ages:
Between 9 years and 25 years
Trial Updated:
02/10/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Acute Respiratory Distress Syndrome, Sepsis, Cardiovascular Shock
Register for Updates
An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks
NCT05617391
Recruiting
The participant is being asked to take part in this trial, because the participant is a survivor of childhood cancer. Primary Objective To evaluate remote cardiomyopathy prediction via smartwatch and one clinical ECG and assess the concordance of the two ECGs in terms of predicted risk. Secondary Objective To build a novel predictive model solely on smartwatch ECG to predict risk for cardiomyopathy.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/10/2025
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Childhood Cancer, Cardiomyopathy, Primary
Register for Updates
Vertebral Artery Origin Treatment Via Endovascular Techniques Registry (VOTER)
NCT03999983
Recruiting
A retrospective and prospective registry of patients admitted for stroke and evidence of Vertebral Artery Origin Stenosis (VAOS).
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
02/10/2025
Locations: Semmes Murphey Clinic, Memphis, Tennessee
Conditions: Vertebral Artery Stenosis
Register for Updates
To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC)
NCT04894591
Recruiting
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Baptist Cancer Center, Memphis, Tennessee
Conditions: Extensive-stage Small-cell Lung Cancer
Register for Updates